Great Point Partners LLC Reduces Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Great Point Partners LLC decreased its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 1.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 402,015 shares of the company’s stock after selling 5,535 shares during the period. Jasper Therapeutics comprises approximately 1.7% of Great Point Partners LLC’s holdings, making the stock its 22nd largest holding. Great Point Partners LLC owned approximately 2.67% of Jasper Therapeutics worth $9,126,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Opaleye Management Inc. purchased a new position in Jasper Therapeutics in the 4th quarter worth about $3,144,000. Kingdon Capital Management L.L.C. increased its position in shares of Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after acquiring an additional 500,000 shares during the period. Concurrent Investment Advisors LLC bought a new stake in shares of Jasper Therapeutics during the first quarter valued at approximately $599,000. Russell Investments Group Ltd. purchased a new stake in shares of Jasper Therapeutics in the first quarter valued at approximately $2,343,000. Finally, StemPoint Capital LP bought a new position in Jasper Therapeutics in the first quarter worth approximately $3,794,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Trading Down 9.8 %

Shares of JSPR stock opened at $21.54 on Tuesday. The company has a market cap of $324.40 million, a PE ratio of -3.83 and a beta of 2.22. Jasper Therapeutics, Inc. has a 12-month low of $4.00 and a 12-month high of $31.01. The business’s fifty day simple moving average is $19.78 and its 200-day simple moving average is $22.65.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. On average, equities analysts forecast that Jasper Therapeutics, Inc. will post -4.16 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Stifel Nicolaus began coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They issued a “buy” rating and a $86.00 price target for the company. Royal Bank of Canada dropped their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Finally, Evercore ISI reissued an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of “Buy” and an average target price of $73.00.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.